Quantcast
Last updated on April 19, 2014 at 7:10 EDT

Latest Infectious Disease Research Institute Stories

2014-03-24 08:28:06

Progress on New Drug Development Continues as World TB Day is Observed Today, March 24 SEATTLE, March 24, 2014 /PRNewswire-USNewswire/ -- IDRI's drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding was awarded to Tanya Parish, Ph.D., IDRI's Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million. The grant is focused...

2014-03-18 23:01:18

The Washington State Tuberculosis Action Coalition (WSTAC) will host an educational event for the community to raise awareness about the burden of TB both globally and locally. Seattle, WA (PRWEB) March 18, 2014 WHAT:    The Washington State Tuberculosis Action Coalition (WSTAC) will host an open community event to raise awareness about the burden of TB both globally and in our own backyard. Experts in the field from Seattle BioMed, Infectious Disease Research...

2013-11-04 08:26:49

Solutions company to improve the efficacy of public health and bioterror countermeasures by developing, manufacturing, applying and testing a novel adjuvant for West Nile virus and anthrax vaccine candidates. RESTON, Va., Nov. 4, 2013 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, announced it has been awarded a prime vaccine adjuvant development contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of...

2013-07-25 12:27:25

SEATTLE and AHMEDABAD, India, July 25, 2013 /PRNewswire-USNewswire/ -- In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis (VL) vaccine candidate, designed to prevent the deadly parasitic disease. (Logo:...

2013-04-18 10:04:12

All 3 configurations of adjuvant and route of administration exceeded the 3 CHMP criteria IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs),...

2013-04-17 16:25:56

- All three configurations of adjuvant and route of administration exceeded the three CHMP criteria- QUEBEC CITY, and SEATTLE, WA, April 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a...

2013-04-09 08:29:23

-Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant- QUEBEC CITY, and SEATTLE, WA, April 9, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG); (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and, IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a...

2013-04-09 08:29:06

Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant SEATTLE and QUEBEC CITY, April 9, 2013 /PRNewswire/ -- IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines...

2013-01-24 08:31:45

Marking Progress in Advance of World Leprosy Day, Observed Jan. 27 SEATTLE and RIO DE JANEIRO, Jan. 24, 2013 /PRNewswire-USNewswire/ -- IDRI (Infectious Disease Research Institute), in conjunction with OrangeLife, a Brazilian diagnostic company, today announces the registration of a rapid diagnostic test for leprosy, offering new hope for early diagnosis and treatment. The test was registered through ANVISA, Brazil's regulatory authority. (Logo:...

2012-06-27 02:26:51

PRINCETON, N.J., June 27, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, WA to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform (known as ThermoVax(TM)). Synthetic...